JINYU(600201) 证券日报·2025-04-27 22:48Core Viewpoint - The company has disclosed its quarterly report, ensuring the accuracy and completeness of financial information, and has undertaken legal responsibilities for any misrepresentation or omissions [2][3]. Financial Data - The company has not restated or adjusted previous accounting data and confirms that non-recurring gains and losses are applicable, specifically mentioning the refund of personal income tax handling fees as a non-recurring item [3][4]. - As of February 5, 2025, the company has repurchased a total of 1,028,148 shares, accounting for 0.95% of the total share capital, with a total transaction amount of approximately 41.99 million yuan [6]. Shareholder Information - The company has not reported any changes in the top ten shareholders or the status of shares lent out for margin trading [5]. Other Important Matters - The company has established a wholly-owned subsidiary in Germany, "Highfine Biotech GmbH," with a registered capital of 200,000 euros, aimed at enhancing its competitive edge and expanding its market presence in Europe [7]. - The company’s production capacity is being expanded, with the first phase of its Anhui production base having commenced operations in August 2022, and a new project expected to obtain production licenses by January 2025 [9].